What is the logic behind Huadong Medicine's two-day daily limit?

2015，870。

，，1760。

2019，，2560。

，，。1367.

，“”。，。

，，？，“”？

01 ，？

。

413，，Sinclair(Ellans)，。，。

414，。

The new type of collagen stimulant Ellanse, commonly known as "Girl Needle", is considered a combination of "Hyaluronic Acid + Tong Yan Needle".

In recent years, by integrating global medical beauty resources, Huadong Medicine has deeply cultivated the medical beauty industry, and its product structure has been continuously optimized, and its medical beauty internationalization results have also continued to appear.

The exploration began in 2013.

In 2013, Huadong Medicine obtained the exclusive domestic agency right of Ewan Hyaluronic Acid through the cooperation between its subsidiary Huadong Ningbo Company and South Korea's LG Company.

In 2018, Huadong Medicine acquired all the shares of Sinclair, a British medical beauty company, at a price of 169 million pounds.

In February 2021, through its wholly-owned subsidiary Sinclair, Huadong Medicine acquired the entire equity of Spanish energy-source medical equipment company High Technology Products, SLU at a price of 65 million euros (approximately RMB 506 million).

In addition, Huadong Medicine also cooperated with Jiuyuan Gene to obtain the development technology of its liraglutide weight-loss indication; cooperated with South Korea Jetema to obtain the exclusive agency right of its botulinum toxin products in mainland China.

At present, Huadong Medicine has formed four global R&D centers, which are wholly-owned subsidiaries Sinclair in the United Kingdom, High Tech in Spain, and its shareholding companies R2 and Kylane in Switzerland.

From the perspective of product line, the current medical beauty products of Huadong Medicine include hyaluronic acid, botulinum toxin, girl needles, thread embedding, liraglutide weight loss products and photoelectric medical beauty equipment, covering most of the light medical beauty fields on the market, of which hyaluronic acid , Botox, and Maiden Injection have strong market potential.

Huadong Medicine stated that in the future, it will further integrate R&D resources and capabilities, and continue to develop international high-end medical aesthetics technology and core products in the fields of facial fillers, body shaping, thread embedding, and energy source devices, and actively optimize and upgrade the product structure to enrich Improve the industrial layout.

As an established domestic pharmaceutical company, Huadong Medicine was established in 1993, listed on the Shenzhen Stock Exchange in 1999, and listed on the A-share market in 2000.

In addition to the medical beauty industry, Huadong Medicine's main business includes two parts: the pharmaceutical business and the pharmaceutical industry.

From the 2019 annual report of Huadong Medicine, the pharmaceutical business contributed most of the revenue, but the pharmaceutical industry was the main source of profit.

Compared with these two pillars, the medical beauty industry has obviously not yet become a new growth point for Huadong Medicine.

According to the 2019 annual report, the annual revenue of East China's medical aesthetics industry in the domestic and foreign markets exceeded 1.

The 2020 annual report of Huadong Medicine will be released soon.
It is worth looking forward to how the accelerated medical beauty sector will perform in 2020.

02 The second battlefield for pharmaceutical companies?

Not only Huadong Medicine, in recent years, many pharmaceutical companies have announced their entry into the medical beauty track.

Sihuan Pharmaceutical is also a pharmaceutical company that started to deploy medical beauty earlier.

As early as 2014, Sihuan Pharmaceutical signed an exclusive agency agreement with South Korean biopharmaceutical company Hugel to jointly develop its botulinum toxin and hyaluronic acid products in the Chinese market.
In October 2020, Hugel botulinum toxin type A for injection (Letybo 100U, trade name: Le Tibao) was approved for marketing, and it was officially listed on February 4 this year, becoming the fourth type A meat approved to be marketed in China Toxins.

Public information shows that Sihuan Medicine has a number of blockbuster medical beauty products in its product line.
Hugel hyaluronic acid, its sole agent, has submitted a product registration application and is expected to be approved for sale in China by the end of 2021; it can improve wrinkles and scars The self-developed Sihuan medical beauty product Tongyan Gel is expected to be approved by the end of 2022; the anti-aging and anti-aging first-generation Tongyan injection filler and the second-generation girl injection that stimulate collagen proliferation are both in In the animal experiment phase, it is expected to be declared in 2023.
In addition, more than 10 self-developed products, such as composite collagen fillers, liraglutide project, and fat-dissolving drugs for partially improving fat containers, are under development and approval.

The analysis pointed out that as Sihuan's medical aesthetics products are successively listed, a matrix of medical aesthetics products will be gradually formed and will gradually provide new profit points for its performance growth.

Kangzhe Pharmaceutical, which is also a Hong Kong-listed company with Sihuan Pharmaceutical, has also begun to enter the medical beauty market through acquisitions.

On February 1, CMS announced that it had acquired all the issued shares of LuqaVentures Co.
, Limited, a skin line specialist company, from a number of third-party sellers through its wholly-owned subsidiary.
For this acquisition, CMS believes that the skin treatment and medical aesthetics market has a bright future.
In order to expand its market position, one of the development strategies of CMS is to enrich the product matrix and expand the territory of related fields through diversification.

Prior to this, pharmaceutical companies such as Pien Tze Huang, Fosun Pharmaceutical, and Shuanglu Pharmaceutical also made new moves in the cosmetics business.

In October 2019, Pien Tze Huang announced that it would spin off its cosmetics segment for listing.
Pien Tze Huang plans to spin off the holding subsidiary of Fujian Pien Tze Huang Cosmetics Co.
, Ltd.
, which has brands such as "Pien Tze Huang" and "Queen", and its products cover skin care products, cleansing and care products.

In September 2020, Hunan Dongting Pharmaceutical, a holding company of Fosun Pharma, invested in the establishment of Hunan Dongting Kangyan Biotechnology Co.
, Ltd.
, and holds 68% of the shares.
One of the company’s main businesses is cosmetics manufacturing and sales; Shuanglu Pharmaceuticals is engaged in cosmetics There have also been moves in business.
The domestic non-special use cosmetics containing hemp extract submitted by its holding subsidiary, Haibu Biological, have been approved.

Why do pharmaceutical companies favor cross-border medical beauty?

"The reason why pharmaceutical companies cross-border medical aesthetics is more or less related to the resistance to the development of their main business.
" Industry analysis pointed out that due to the impact of mass procurement, medical insurance control fees and other medical reform policies, pharmaceutical companies are under increasing pressure to survive and need to be explored.
New profit growth point.

At the same time, "medical beauty", which is one word short of "medicine", is entering its golden age.

As the world's second largest medical aesthetics market, it is predicted to surpass the United States in 2023 to become the world's largest medical aesthetics market.
Brokerage analysis believes that the supply of medical beauty products is iteratively upgraded, consumption growth in lower-tier cities and the "post-90s" population will increase the penetration rate, and the repurchase habits of medical beauty consumption will promote market expansion.
The next 5-10 years will be the development of the medical beauty track.
In the golden age, it is predicted that the scale of the medical beauty market in 2024 is expected to exceed 300 billion yuan.
Pharmaceutical companies have certain R&D advantages in the process of cross-border medical beauty.
The analysis pointed out that compared with the pharmaceutical industry, medical beauty and cosmetics have lower R&D risks and higher product gross profit margins.

Original title: What is the logic behind Huadong Medicine's two-day daily limit? Is medical beauty a gimmick or a new growth point? There are hundreds of billions of track participants and them!